Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15019206rdf:typepubmed:Citationlld:pubmed
pubmed-article:15019206lifeskim:mentionsumls-concept:C0599779lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0031955lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0036983lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C0768986lld:lifeskim
pubmed-article:15019206lifeskim:mentionsumls-concept:C1527211lld:lifeskim
pubmed-article:15019206pubmed:issue11lld:pubmed
pubmed-article:15019206pubmed:dateCreated2004-3-15lld:pubmed
pubmed-article:15019206pubmed:abstractTextThe therapeutic efficacy of protegrin peptide IB-367 was investigated in three rat models of septic shock: (i) rats injected intraperitoneally with 1mg Escherichia coli 0111:B4 lipopolysaccharide, (ii) rats given an intraperitoneal injection of 2 X 10(10) CFU of E. coli ATCC 25922, and (iii) rats in which intra-abdominal sepsis was induced via cecal ligation and puncture. All animals were randomized to receive parenterally isotonic sodium chloride solution, 1mg/kg of IB-367, 60mg/kg piperacillin and 1mg/kg of IB-367 plus 60mg/kg piperacillin. The peptide demonstrated lower level of antimicrobial activity than piperacillin, nevertheless it exhibited the dual properties of antimicrobial and antiendotoxin agent. Finally IB-367 and piperacillin association showed to be the most effective therapeutic approach.lld:pubmed
pubmed-article:15019206pubmed:languageenglld:pubmed
pubmed-article:15019206pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:citationSubsetIMlld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15019206pubmed:statusMEDLINElld:pubmed
pubmed-article:15019206pubmed:monthNovlld:pubmed
pubmed-article:15019206pubmed:issn0196-9781lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:CirioniOscarOlld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:GiacomettiAnd...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:GhiselliRober...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:MocchegianiFe...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:OrlandoFioren...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:SabaVittorioVlld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:ScaliseGiorgi...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:KamyszWojciec...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:ViticchiClaud...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:D'AmatoGiusep...lld:pubmed
pubmed-article:15019206pubmed:authorpubmed-author:?LukasiakJerz...lld:pubmed
pubmed-article:15019206pubmed:issnTypePrintlld:pubmed
pubmed-article:15019206pubmed:volume24lld:pubmed
pubmed-article:15019206pubmed:ownerNLMlld:pubmed
pubmed-article:15019206pubmed:authorsCompleteYlld:pubmed
pubmed-article:15019206pubmed:pagination1747-52lld:pubmed
pubmed-article:15019206pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:meshHeadingpubmed-meshheading:15019206...lld:pubmed
pubmed-article:15019206pubmed:year2003lld:pubmed
pubmed-article:15019206pubmed:articleTitleAntiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.lld:pubmed
pubmed-article:15019206pubmed:affiliationInstitute of Infectious Diseases and Public Health, Clinica delle Malattie Infettive, Università Politecnica delle Marche, c/o Ospedale Regionale, Via Conca, 60020 Torrette AN, Ancona, Italy. anconacmi@interfree.itlld:pubmed
pubmed-article:15019206pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15019206pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed